FGFR3 overexpression	Urothelial Cancer	FGFR3 overexpression	Urothelial Cancer	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2
FGFR3 overexpression	Head and Neck Cancer	FGFR3 overexpression	Head and Neck Cancer	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR3 overexpression	Lung Non-Small Cell Squamous Cancer	FGFR3 overexpression	Lung Non-Small Cell Squamous Cancer	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3
FGFR3 overexpression	Urothelial Cancer	FGFR3 overexpression	Urothelial Cancer	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR3 overexpression	Breast Cancer	FGFR3 overexpression	Breast Cancer	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR3 overexpression	Bladder Cancer	FGFR3 overexpression	Bladder Cancer	futibatinib Sensitive: D – Preclinical futibatinib Sensitive : D	futibatinib Sensitive: D – Preclinical futibatinib Sensitive : D
FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck	FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck	BAY 1163877 Sensitive: D – Preclinical BAY 1163877 Sensitive : D	BAY 1163877 Sensitive: D – Preclinical BAY 1163877 Sensitive : D
FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck	FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D
FGFR3 overexpression	Breast Cancer	FGFR3 overexpression	Breast Cancer	FGFR inhibitor Sensitive: D – Preclinical FGFR inhibitor Sensitive : D	FGFR inhibitor Sensitive: D – Preclinical FGFR inhibitor Sensitive : D
FGFR3 overexpression	Bladder Cancer	FGFR3 overexpression	Bladder Cancer	AMB302 Sensitive: D – Preclinical AMB302 Sensitive : D	AMB302 Sensitive: D – Preclinical AMB302 Sensitive : D
FGFR3 overexpression	Glioblastoma	FGFR3 overexpression	Glioblastoma	AMB302 Sensitive: D – Preclinical AMB302 Sensitive : D	AMB302 Sensitive: D – Preclinical AMB302 Sensitive : D

FGFR3 overexpression

Associations